• 4μ8C: Precision Control of ER Stress Signaling

  2026-09-01

  4μ8C is a selective IRE1α RNase tool for separating ER stress sensing from downstream signaling. This thought-leadership guide connects its use in hypoxia and cancer research with broader lessons in proteostasis, experimental validation, and translational decision-making.

• Dynasore for Endocytosis Research

  2026-08-31

  Dynasore enables reversible, dose-dependent disruption of dynamin-dependent membrane scission for mechanistic studies of nanoparticle uptake, receptor trafficking, and synaptic vesicle recycling. This workflow-centered guide shows how to pair a dynamin GTPase inhibitor with viability controls and pathway-aware interpretation, particularly in human corneal epithelial cell assays.

• Baricitinib for JAK1/2 and PSC Assays

  2026-08-31

  Baricitinib (LY3009104) converts spatially observed IL-6 activity into a testable JAK1/2 perturbation workflow. This guide covers dose finding, phospho-STAT3 readouts, epithelial–immune co-culture design, and troubleshooting for PSC, inflammatory signaling, and preclinical arthritis studies.

• Triamcinolone: Protocol and QC Guidance

  2026-08-30

  Triamcinolone (SKU B1859) provides a defined synthetic glucocorticoid agonist for controlled in vitro studies of glucocorticoid receptor signaling, inflammation, and immunosuppression. It is a research-use reagent only; its water and ethanol insolubility, DMSO handling requirements, and limited solution-storage stability must be considered during assay design.

• Telmisartan Workflow for Cardiac Hypertrophy

  2026-08-29

  Use Telmisartan as an AT1-receptor-centered control in angiotensin II cardiac hypertrophy models, then compare upstream receptor blockade with downstream RIP3/CaMKII interventions. This workflow combines solvent-aware handling, dose-range design, orthogonal phenotyping, and troubleshooting for reproducible cardiovascular disease research.

• S63845 and the Context of MCL1-Driven Apoptosis

  2026-08-28

  S63845 is a selective MCL1 inhibitor that converts anti-apoptotic dependency into a measurable mitochondrial death response. This thought-leadership perspective connects its mechanism to ferroptosis–apoptosis crosstalk and provides translational guidance for model selection, assay design, combination studies, and preclinical interpretation.

• Flubendazole in Metabolic Fibrosis Models

  2026-08-28

  Flubendazole can help researchers examine how autophagy intersects with glutamine metabolism and hepatic stellate cell activation. This article translates a SIRT4–GDH liver fibrosis study into a careful experimental framework while separating evidence-based interpretation from exploratory use.

• Bleomycin Sulfate: From DNA Damage to Fibrosis

  2026-08-27

  Bleomycin Sulfate, also known as Blenoxane, is more than a cytotoxic research reagent. Its metal-dependent generation of activated oxygen species creates a controllable DNA strand-break signal that can be connected to inflammation, fibrosis, and tissue remodeling. This thought-leadership guide examines how to use the compound in oncology and pulmonary fibrosis research, while integrating findings from an iScience study linking bleomycin-induced systemic sclerosis to the miR-4769-3p–USP18/VDAC2 adipogenesis axis.

• SB-505124 Hydrochloride in Signaling Assays

  2026-08-27

  SB-505124 hydrochloride provides a reversible way to separate TGF-β/activin pathway signaling from nonspecific toxicity in fibrosis, epithelial, and mechanobiology assays. This guide translates ALK4/5/7 inhibition into practical workflows, controls, and troubleshooting strategies, including how to interpret results alongside cancer-cell stiffness studies.

• KU-60019 Workflows for ATM Inhibition Research

  2026-08-26

  Build reproducible glioma experiments around KU-60019, an ATM kinase inhibitor that combines DNA damage response inhibition with radiosensitization and migration assays. A metabolism-aware workflow also tests whether ATM suppression shifts nutrient scavenging toward macropinocytosis, creating a practical bridge between radiation biology and tumor-cell adaptation.

• Hepatic sEH–Nrf2 Axis in Osteoporosis

  2026-08-26

  A 2025 study identifies a liver–bone axis in which hepatic soluble epoxide hydrolase reshapes circulating 14,15-EET and 14,15-DHET, inflammatory signaling, and Nrf2-dependent osteoclastogenesis. By combining patient samples, an ovariectomy-induced mouse model, liver-specific perturbation, osteoclast cultures, metabolite analysis, and transcriptomics, the work provides a mechanistic framework for studying redox imbalance in osteoporosis.

• Vitamin D/VDR Signaling in Endometrial Decidualization

  2026-08-25

  Guo and colleagues show that vitamin D promotes human endometrial stromal cell decidualization through VDR-dependent regulation of aromatase and estrogen signaling. The study combines loss- and gain-of-function experiments with ChIP-qPCR, providing a mechanistic framework for evaluating 1,25-dihydroxy vitamin D3 in endometrial receptivity research.

• Anti-ROR1 Antibody: Assay Logic for Zilovertamab

  2026-08-25

  Anti-ROR1 Antibody (Zilovertamab) can do more than confirm ROR1 binding: it can anchor a decision-based assay strategy for target engagement, pathway modulation, and translational interpretation. This article connects ROR1 assay design with mechanistic lessons from DON-induced liver injury without implying untested cross-disease efficacy.

• Saracatinib (AZD0530): From Src Biology to Translation

  2026-08-24

  Saracatinib (AZD0530) offers translational researchers a mechanistically focused way to interrogate Src family kinase and Abl signaling across cancer models. This article connects its effects on proliferation, migration, adhesion, and tumor growth with emerging evidence that SFK-dependent synaptic signaling can also shape ketamine responsiveness—while clearly separating established findings from cross-domain hypotheses.

• WZ4003 Lowers Tau pSer356 in Brain Models

  2026-08-24

  Taylor et al. linked tau phosphorylation at Ser356 to Alzheimer’s disease pathology and showed that the NUAK1/2 inhibitor WZ4003 lowers this modification in live human brain slice cultures. The study also reveals important model-dependent effects in mouse organotypic slices, providing a framework for interpreting NUAK inhibition in translational neurodegeneration research.

8446 records 9/564 page Previous Next First page 上5页 678910 下5页 Last page